Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cocrystal Pharma, Inc. filings document material-event disclosures for a clinical-stage antiviral drug developer. Recent 8-K reports furnish press releases on CDI-988, including norovirus program updates, FDA Fast Track designation, scientific conference presentations and annual financial results tied to the antiviral pipeline.
The company’s filings also record Nasdaq Capital Market status, board and executive compensation matters under the 2025 Equity Incentive Plan, stock-option grants and director changes, along with Regulation FD disclosures and exhibits related to clinical and business updates.
Cocrystal Pharma, Inc. appointed James Sapirstein as Chief Executive Officer, effective immediately, under an employment offer letter. He will receive an initial annual base salary of $265,000 and an annual performance bonus targeted at 50% of base salary, tied to Board-set goals.
Sapirstein was granted 10-year stock options to purchase 235,000 shares at an exercise price of $1.05, vesting in four equal annual installments beginning June 3, 2027, with accelerated vesting upon a Change in Control or certain terminations. The Offer Letter also contemplates a potential additional grant of options to purchase another 235,000 shares six months after his start date, subject to performance targets and approvals. He replaces prior Co-CEOs Sam Lee and James Martin, who continue as President/Chief Scientific Officer and Chief Financial Officer, respectively.
Cocrystal Pharma, Inc. reported that Chief Executive Officer James Sapirstein received a grant of stock options to acquire 235,000 shares of common stock. The options have an exercise price of $1.12 per share and expire on June 3, 2036.
The options were granted under the company’s 2025 Equity Incentive Plan at no cost, vesting in four equal annual installments starting on June 3, 2027, subject to continued employment and potential accelerated vesting upon a Change in Control or termination for Cause as defined in the plan.
Cocrystal Pharma, Inc. filed an initial ownership report on Form 3 for Chief Executive Officer James Sapirstein. This filing establishes his status as an insider but does not list any buy, sell, or derivative transactions, and shows no current holdings or option positions in the data provided.
Cocrystal Pharma has appointed James Sapirstein as Chief Executive Officer, effective immediately, and plans to add him to the Board of Directors. He succeeds former Co-CEOs Sam Lee and Jim Martin; Lee will remain President and become Chief Scientific Officer, while Martin continues as Chief Financial Officer. The company highlights Sapirstein’s extensive antiviral and biopharma leadership experience, including participation in 23 product launches and multiple business development deals. Cocrystal reiterates its focus on structure-based drug discovery to develop next-generation antiviral therapies targeting viruses such as norovirus, influenza, coronaviruses including SARS-CoV-2, and hepatitis C.
Cocrystal Pharma is asking stockholders to vote at its 2026 virtual annual meeting on July 14, 2026. Investors will elect five directors for one-year terms, ratify Weinberg & Company as independent auditor for 2026, and approve a potential adjournment to gather additional votes if needed.
The proxy details how to attend and vote electronically, outlines quorum and broker voting rules, and describes board structure and full independence under Nasdaq standards. It highlights key committees, an insider trading and anti-hedging policy, and a clawback policy tied to financial restatements.
Executive pay in 2025 focused on reduced base salaries and equity awards, with Co-CEOs James Martin and Sam Lee earning $265,000 and $248,672 respectively. The filing shows insiders and directors collectively beneficially owning 39.4% of common stock and reports a 2025 net loss of $8.8 million alongside pay-versus-performance disclosure.
Cocrystal Pharma, Inc. reported new preclinical data showing its novel direct-acting antivirals have pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These molecules target a highly conserved region of the viral replication enzyme, specifically the L-protein of Andes hantavirus, which is essential for replication and transcription.
The Company highlighted in vitro potency data with superior activity, including IC50 values below 50 nM against hantaan virus, a close relative of the Andes hantavirus strain linked to recent outbreaks. Cocrystal also noted that its first pan-viral protease inhibitor, CDI-988, has advanced into a Phase 1b norovirus challenge study in the United States, while it works to develop a pan-viral lead molecule and explore potential collaborations to address viral diseases that currently lack approved treatments or vaccines.
Cocrystal Pharma, Inc. filed a current report describing new clinical and scientific visibility for its oral norovirus drug candidate CDI-988. The company presented mechanism-of-action and early clinical data at the ICAR 2026 antiviral research conference, highlighting completed Phase 1 results and an ongoing Phase 1b human challenge study.
CDI-988, a first oral direct-acting 3CL protease inhibitor for norovirus, was generally safe and well tolerated in a randomized, double-blind, placebo-controlled Phase 1 trial in healthy adults at doses up to 1,200 mg, with no serious adverse events. The Phase 1b challenge trial at Emory University and the University of North Carolina plans to enroll up to 40 adults, with a fully enrolled initial cohort establishing infectivity of the norovirus GII.2 inoculum before prevention and treatment cohorts receiving 1,200 mg twice daily for five days.
The company notes that CDI-988 has U.S. FDA Fast Track designation for treatment and prophylaxis of norovirus infection, a disease with substantial global burden and no approved vaccines or therapies.
Cocrystal Pharma, Inc. files a shelf registration to offer up to $150,000,000 of common stock, preferred stock, warrants and units.
The shelf permits sales from time to time and also includes unsold securities from a prior registration statement; the company states net proceeds will be used for working capital and other general corporate purposes.